Boehringer Ingelheim Pharmaceuticals and the Duke Clinical Research Institute (DCRI) are expanding the Idiopathic Pulmonary Fibrosis PROspective Outcomes Registry (IPF-PRO), which they say will make it the largest IPF patient registry in the country. The ... Read more